876 related articles for article (PubMed ID: 33217030)
1. Antiretrovirals for Prophylaxis Against COVID-19: A Comprehensive Literature Review.
Alavian G; Kolahdouzan K; Mortezazadeh M; Torabi ZS
J Clin Pharmacol; 2021 May; 61(5):581-590. PubMed ID: 33217030
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection.
Copertino DC; Casado Lima BC; Duarte RRR; Powell TR; Ormsby CE; Wilkin T; Gulick RM; de Mulder Rougvie M; Nixon DF
J Biomol Struct Dyn; 2022 Oct; 40(16):7367-7380. PubMed ID: 33734021
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention.
Yap PK; Loo Xin GL; Tan YY; Chellian J; Gupta G; Liew YK; Collet T; Dua K; Chellappan DK
J Pharm Pharmacol; 2019 Sep; 71(9):1339-1352. PubMed ID: 31144296
[TBL] [Abstract][Full Text] [Related]
4. Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19?
Dallocchio RN; Dessì A; De Vito A; Delogu G; Serra PA; Madeddu G
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2435-2448. PubMed ID: 33755983
[TBL] [Abstract][Full Text] [Related]
5. The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2.
Feng JY; Du Pont V; Babusis D; Gordon CJ; Tchesnokov EP; Perry JK; Duong V; Vijjapurapu A; Zhao X; Chan J; Cohen C; Juneja K; Cihlar T; Götte M; Bilello JP
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807457
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection.
Zanella I; Zizioli D; Castelli F; Quiros-Roldan E
Pharmaceuticals (Basel); 2021 May; 14(5):. PubMed ID: 34064831
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2.
Mondi A; Cimini E; Colavita F; Cicalini S; Pinnetti C; Matusali G; Casetti R; Maeurer M; Vergori A; Mazzotta V; Gagliardini R; De Zottis F; Schininà V; Girardi E; Puro V; Ippolito G; Vaia F; Capobianchi MR; Castilletti C; Agrati C; Antinori A
J Med Virol; 2021 Mar; 93(3):1796-1804. PubMed ID: 32975842
[TBL] [Abstract][Full Text] [Related]
8. Retrospective evaluation of an observational cohort by the Central and Eastern Europe Network Group shows a high frequency of potential drug-drug interactions among HIV-positive patients receiving treatment for coronavirus disease 2019 (COVID-19).
Lakatos B; Kowalska J; Antoniak S; Gokengin D; Begovac J; Vassilenko A; Wasilewski P; Fleischhans L; Jilich D; Matulionyte R; Kase K; Papadopoulus A; Rukhadze N; Harxhi A; Hofman S; Dragovic G; Vasyliev M; Verhaz A; Yancheva N; Oprea C;
HIV Med; 2022 Jul; 23(6):693-700. PubMed ID: 34859557
[TBL] [Abstract][Full Text] [Related]
9. Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro.
Zhang L; Liu J; Cao R; Xu M; Wu Y; Shang W; Wang X; Zhang H; Jiang X; Sun Y; Hu H; Li Y; Zou G; Zhang M; Zhao L; Li W; Guo X; Zhuang X; Yang XL; Shi ZL; Deng F; Hu Z; Xiao G; Wang M; Zhong W
Virol Sin; 2020 Dec; 35(6):776-784. PubMed ID: 32910347
[TBL] [Abstract][Full Text] [Related]
10. HIV exposure through contact with body fluids.
Prescrire Int; 2012 Apr; 21(126):100-1, 103-5. PubMed ID: 22515138
[TBL] [Abstract][Full Text] [Related]
11. Ivermectin for preventing and treating COVID-19.
Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
[TBL] [Abstract][Full Text] [Related]
12. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
Abdizadeh R; Hadizadeh F; Abdizadeh T
Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
[TBL] [Abstract][Full Text] [Related]
13. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
14. Computational drug repurposing for the identification of SARS-CoV-2 main protease inhibitors.
Fiorucci D; Milletti E; Orofino F; Brizzi A; Mugnaini C; Corelli F
J Biomol Struct Dyn; 2021 Oct; 39(16):6242-6248. PubMed ID: 32705942
[TBL] [Abstract][Full Text] [Related]
15. A Review on the New Indication of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in the Treatment of Coronavirus Disease 2019.
Karbasforooshan H; Salari S; Hosseinjani H
Infect Disord Drug Targets; 2022; 22(5):e180222201281. PubMed ID: 35184718
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
17. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC
J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022
[TBL] [Abstract][Full Text] [Related]
18. Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial.
Tan DHS; Chan AK; Jüni P; Tomlinson G; Daneman N; Walmsley S; Muller M; Fowler R; Murthy S; Press N; Cooper C; Lee T; Mazzulli T; McGeer A
Trials; 2021 Mar; 22(1):224. PubMed ID: 33752741
[TBL] [Abstract][Full Text] [Related]
19. Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.
Fintelman-Rodrigues N; Sacramento CQ; Ribeiro Lima C; Souza da Silva F; Ferreira AC; Mattos M; de Freitas CS; Cardoso Soares V; da Silva Gomes Dias S; Temerozo JR; Miranda MD; Matos AR; Bozza FA; Carels N; Alves CR; Siqueira MM; Bozza PT; Souza TML
Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32759267
[TBL] [Abstract][Full Text] [Related]
20. In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors.
Ibrahim MAA; Abdelrahman AHM; Allemailem KS; Almatroudi A; Moustafa MF; Hegazy MF
Protein J; 2021 Jun; 40(3):296-309. PubMed ID: 33387249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
